Our Latest Pick – SNPK – breaks the .70′s
Global Investment Alert Newsletter
It was another great day for our latest pick – SNPK! SNPK traded hard and broke through the .70 cent level in a late day rally! Today could see an early pull back as some take profits but SNPK should continue it`s run to the $1.00 level – and beyond! Latest Company News:
Sunpeaks Ventures Announces Clotamin to be Sold in Approximately 70 Discount Drug Mart Locations in Ohio – Professional Sports Team Marketing Campaign Expected to Increase Sales SILVER SPRING, Md., March 12, 2012 /PRNewswire via COMTEX/ — Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the “Company” or “Sunpeaks Ventures”) and its wholly owned subsidiary Healthcare Distribution Specialists, LLC (“HDS”) are pleased to announce that Clotamin will soon be available in approximately 70 Discount Drug Mart (“DDM”) retail locations in Ohio. In addition, Clotamin will be included in the Pro Points Program, DDM`s signature customer rewards program. DDM customers may redeem their Pro Points for merchandise, game tickets, and one-of-a-kind lifetime experiences with professional local sports teams including the Indians, Cavaliers, Browns, Lake Erie Monsters (hockey), and Cleveland Gladiators (arena football). Pro Points rewards include the opportunity to shoot hoops on the Cleveland Cavaliers basketball court before warm-ups and autographed baseballs from your favorite Cleveland Indians baseball players. Participating partner companies are included in a comprehensive advertising campaign at all participating team events. The complete advertising campaign is valued up to $250,000 and could have an incremental sales increase of up to 60%, according to DDM.
“DDM is one of the leading retailers in the Ohio market and their Pro Points Program really separates them from their local competition,” stated Mackie A.
Barch, CEO of Sunpeaks. “The Pro Points Program will allow Clotamin to be marketed simultaneously to multiple professional sports team fan bases and represents an entirely new potential customer audience for Clotamin. This could have major positive sales implications for Clotamin and provides excellent advertising value for the Company and it shareholders.” Clotamin is the world`s first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin or other anticoagulants (blood thinners). According to BioMed Trends, in a report released by Global Industry Analysts, Inc., the global anticoagulants market is projected to surpass $11.2 billion by the year 2015, driven by an aging global population, rising incidence of cardiovascular diseases, cancers, and acute hip and knee complications, as well as emergence of innovative therapeutics targeting new and previously targeted clotting factors.
SNPK is far from over. Once SNPK breaks through the $1.00 there`s no telling how high it could go! The GIA Staff ___________________________________________________________________________ All information on featured companies is provided by the companies profiled, or is available from public sources and GIA, Inc. makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. GIA, Inc., nor any of its affiliates are not registered investment advisors or a broker dealers. GIA, Inc. has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor`s sole risk. GIA, Inc. has also been advised that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies.
Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk.
It is possible that an investor`s entire investment may be lost or impaired due to the speculative nature of the companies profiled. GIA, Inc. makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through GIA, Inc.. GIA, Inc. expects to receive up to $100,000 from a non-affiliated third party, CNF Inc., for one weeks coverage of SNPK. GIA, Inc.
owners may or may not hold positions in the companies that are profiled.
Investing in securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor`s investment may be lost or impaired due to the speculative nature of the companies profiled.
This message was sent to from:
Global Investment Alert | PO Box 80636 | Tampa, FL 33602
Related posts:
- Reminder *STVF* is my brand new 85 cent hot pick
- UFFC just broke ground on their 2nd of three new locations set to open this month!
- SNPK Rockets up 38%!
- →_SNPK_and_UFFC_provide_solid_gains_today_←
- Our Latest and Greatest Delivers More Gains Today–Should we get greedy?